<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03147053</url>
  </required_header>
  <id_info>
    <org_study_id>XiyuanH</org_study_id>
    <nct_id>NCT03147053</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Jiedu Tongluo Granules for Post-stroke Depression</brief_title>
  <official_title>The Efficacy and Safety of Jiedu Tongluo Granules on Patients With Post-stroke Depression: a Double-blind, Randomized and Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiyuan Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiyuan Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the efficacy and safety of Jiedu Tongluo granules for post stroke depression. A
      randomized, double-blind, placebo-controlled clinical trial was designed. The treatment group
      was administered the Jiedu Tongluo granules, while the control group was administered the
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of 17-item Hamilton Depression Scale( HAMD-17) From Baseline</measure>
    <time_frame>4weeks,8weeks</time_frame>
    <description>Depression symptoms are mainly measured by the 17-item Hamilton Depression Scale (HAMD-17)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Barthel Index (BI) From Baseline</measure>
    <time_frame>4weeks,8weeks</time_frame>
    <description>The daily activities will be measured using Barthel Index(BI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of National Institute of Health stroke scale（NIHSS）From Baseline</measure>
    <time_frame>4weeks,8weeks</time_frame>
    <description>Neurological function mainly measured by NIHSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The stroke diagnosis and evaluation criteria of Traditional Chinese Medicine（TCM）from baseline</measure>
    <time_frame>4weeks,8weeks</time_frame>
    <description>To evaluate patients' syndrome by TCM scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The change of cytokines IL-6、 IL-8 in serum from baseline</measure>
    <time_frame>4weeks,8weeks</time_frame>
    <description>To find the inflammation factors related with post-stroke depression</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Post-stroke Depression</condition>
  <arm_group>
    <arm_group_label>Jiedu Tongluo granules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group were administered the Jiedu Tongluo granules .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this group were administered the placebo .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jiedu Tongluo granules</intervention_name>
    <description>Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.</description>
    <arm_group_label>Jiedu Tongluo granules</arm_group_label>
    <other_name>The treatment group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>The control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of stroke, with neurological deficits symptoms;

          -  Clinical diagnosis of depression, according to the Diagnostic and Statistical Manual
             of Mental Disorders-IV （DSM-IV）or Chinese Classification and Diagnostic Criteria of
             Mental Disorders-3(CCMD-3), the score is between 7 to 24 by 17-item Hamilton
             Depression;

          -  Age of 45 to 80 years old;

          -  The patient is conscious, cooperation, without aphasia and severe cognitive impairment
             after acute phase of stroke;

          -  Without psychiatric disease history or family history of psychosis before stroke;

          -  No hormones and psychotropic drugs were used within 1 month before enrollment;

          -  capacity to provide written consent.

        Exclusion Criteria:

          -  With brain organic disease such as brain tumors;

          -  Had a history of psychiatric illness or depression before stroke;

          -  Combined with severe liver, kidney, hematopoietic system disorder;

          -  Poor glycemic control and insulin-dependent diabetes;

          -  Participate in any clinical trial or taking antidepressant treatment 1 month prior to
             baseline;

          -  Pregnant or breast feeding;

          -  History of sensitivity to Chinese medicine ingredients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianxun Liu</last_name>
    <role>Study Director</role>
    <affiliation>xiyuan hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aimei Zhao</last_name>
    <phone>+8601062835609</phone>
    <email>zhaoaimei@bucm.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiyuan Hospital of China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimei Zhao</last_name>
      <phone>+8601062835609</phone>
      <email>zhaoaimei@bucm.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

